Population-based Study of Biochemical and Survival Outcomes After Permanent 125I Brachytherapy for Low- and Intermediate-risk Prostate Cancer

Urology

Volumn 73, Issue 4, 2009, Pages 860-865

  Morris, W J ^a   Keyes, M ^a   Palma, D ^a   Spadinger, I ^a   McKenzie, M R ^a   Agranovich, A ^b   Pickles, T ^a   Liu, M ^b   Kwan, W ^b   Wu, J ^a   Berthelet, E ^c   Pai, H ^c  

^a British Columbia Cancer Centre   (Canada)

^b British Columbia Cancer Centre   (Canada)

^c British Columbia Cancer Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RADIATION DOSE; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE;

EID: 63149196150     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.07.064     Document Type: Article

References (29)

1. Cooperberg M.R., Lubeck D.P., Meng M.V., et al. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 22 (2004) 2141-2149
2. Blasko J.C., Mate T., Sylvester J.E., et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 12 (2002) 81-94
3. Cesaretti J.A., Stone N.N., Skouteris V.M., et al. Brachytherapy for the treatment of prostate cancer. Cancer J 13 (2007) 302-312
4. Heysek R.V. Modern brachytherapy for treatment of prostate cancer. Cancer Control 14 (2007) 238-243
5. Potters L., Morgenstern C., Calugaru E., et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173 (2005) 1562-1566
6. Zelefsky M.J., Yamada Y., Cohen G.N., et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 67 (2007) 65-70
7. 90 implant doses of 180 Gy or greater. Int J Radiat Oncol Biol Phys 70 (2008) 96-101
8. Merrick G.S., Butler W.M., Galbreath R.W., et al. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys 51 (2001) 41-48
9. Keyes M., Schellenberg D., Moravan V., et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve?. Int J Radiat Oncol Biol Phys 64 (2006) 825-834
10. MacDonald A.G., Keyes M., Kruk A., et al. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important?. Int J Radiat Oncol Biol Phys 63 (2005) 155-163
11. Spadinger I., Hilts M., Keyes M., et al. Prostate brachytherapy postimplant dosimetry: A comparison of suture-embedded and loose seed implants. Brachytherapy 5 (2006) 165-173
12. Bucci J., Morris W.J., Keyes M., et al. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 53 (2002) 91-98
13. Thomas C.W., Kruk A., McGahan C.E., et al. Prostate brachytherapy post-implant dosimetry: A comparison between higher and lower source density. Radiother Oncol 83 (2007) 18-24
14. Morris WJ, Keyes M, Palma D, et al. Evaluation of dosimetric parameters and disease response in 1006 consecutive patients treated with 125-iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. In press.
15. Lukka H., Warde P., Pickles T., et al. Controversies in prostate cancer radiotherapy: Consensus development. Can J Urol 8 (2001) 1314-1322
16. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO, Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
17. Pickles T. Prostate-specific antigen (PSA) bounce and other fluctuations: Which biochemical relapse definition is least prone to PSA false calls?. An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. Int J Radiat Oncol Biol Phys 64 (2006) 1355-1359
18. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
19. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
20. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
21. Cahlon O., Zelefsky M.J., Shippy A., et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 71 (2008) 330-337
22. Stephenson A.J., Kattan M.W., Eastham J.A., et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: A proposal for a standardized definition. J Clin Oncol 24 (2006) 3973-3978
23. Hernandez D.J., Nielsen M.E., Han M., et al. Contemporary evaluation of the D'Amico risk classification of prostate cancer. Urology 70 (2007) 931-935
24. Vicini F., Martinez A., Hanks G., et al. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 95 (2002) 2126-2135
25. Wallace K., Fleshner N., Jewett M., et al. Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: The Toronto experience with the Surgical Prostatectomy Versus Interstitial Radiation Intervention trial. J Clin Oncol 24 (2006) 4158-4162
26. National Cancer Institute. Levels of Evidence for Adult Cancer Treatment Studies (2006), National Cancer Institute, Bethesda
27. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
28. Beyer D.C., McKeough T., and Thomas T. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 1299-1305
29. Merrick G.S., Butler W.M., Wallner K.E., et al. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 65 (2006) 669-677